🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide MASH Phase 2b — March 2026 Page 3

Survodutide MASH Phase 2b — March 2026

CanadaChris Fri, Aug 15, 2025 at 9:27 PM 31 replies 1,956 viewsPage 3 of 7
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
Aug 16, 2025 at 4:05 PM#11
Dr.EM_Chicago said:
If two explanations both fit, the useful question is which one predicts something the other does not.

No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.

25 23NurseKim_ATL, paul_denver, TinaHashiRN and 22 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Aug 17, 2025 at 1:18 AM#12
nancy_portland said:
Agreed, and ALT falling is not the same as fibrosis improving.

This is exactly what I could not find anywhere else. Printing the relevant bit and taking it with me.

Last edited: Aug 17, 2025 at 2:18 AM
26 24BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 23 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Aug 17, 2025 at 10:31 AM#13
Dr.EM_Chicago said:
If two explanations both fit, the useful question is which one predicts something the other does not.

I read this differently from Dr.EM_Chicago, on substance rather than tone. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

27 0MarkLI_maint, Dr.PeteFamMed, claudia_zurich and 24 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Aug 17, 2025 at 7:44 PM#14

The figures, for anyone assembling their own picture. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

Last edited: Aug 17, 2025 at 8:44 PM
28 1hans_munich, jason_sac26, chris_chi24 and 25 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Aug 18, 2025 at 4:57 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. No action needed from anybody.

Last edited: Aug 18, 2025 at 8:57 AM
29 2PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 26 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register